Precipio Updates Commercial Pipeline for its ICE-COLD PCR™ Liquid Biopsy Technology

Precipio (NASDAQ:PRPO) has provided an update to its pipeline of high-volume potential adopters of its ICE COLD-PCR mutation enrichment kits for liquid biopsies with the commencement of eight ICP kit trials and agreements for 12 additional ICP kit trials in Q3 2018.

As quoted in the press release:

The eight ICP trials are underway with three reference laboratories, one hospital laboratory, two with a large contract research organization (CRO) and two diagnostic equipment companies. Results and potential adoption of the testing platform is anticipated within 8-12 weeks.

The 12 agreements for the upcoming ICP kit trials consist of two reference labs, two CROs, seven hospital labs, and a pharma company. In addition, we are in discussions with additional Pharma and Biotech companies about incorporating ICP into their research projects or pipeline.

The initial adoption of ICE COLD-PCR begins with the completion of a successful trial, followed by the validation of testing in their in-house laboratory using the ICEme Kits; and subsequently, commercial orders are placed.

Liquid Biopsy Market

The market for liquid biopsy testing is anticipated to grow from several hundred million in 2016, to over $1B in 2023, according to a 2018 Reuters article¹. Even with this strong market growth, the liquid biopsy market still has tremendous upside potential. The fully penetrated market potential is estimated to exceed $13B annually for therapeutic selection, treatment monitoring and recurrence monitoring, according to a 2015 Piper-Jaffray report.²

Click here to read the full press release.